Vertex Is Firing On All Cylinders But New Drug Launches Remain Challenging

As the architect of the company’s hugely successful business model, Stuart Arbuckle, departs, he hands over a portfolio expanding beyond its cystic fibrosis base, but one that might be slow to build revenues for Casgevy and Journavx.